[CII Membership Roster] [CII Meeting Rosters]

The Cancer Immunopathology and Immunotherapy [CII] Study Section reviews applications addressing immunologic therapies of cancer and modulation of the innate and adaptive immune responses to cancer cells.  This includes in vitro studies, the evaluation of immunotherapeutic strategies in preclinical models, and translational studies leading to pilot and/or phase I clinical trials.  Specific areas covered by CII include:

• Tumor vaccines of all types and dendritic cell-based therapies to induce or amplify tumor immunity
• Therapeutic use of antibodies, conjugated antibodies, or antibody fragments to target tumor cells or to modulate immune response to cancer cells
• Hematopoietic stem cell transplantation and other adoptive cellular therapies with immune cells as cancer treatment
• Modulation of tumor immune response by gene therapy, cytokines, chemokines, growth factors, signal agonists and antagonists, or biological response modifying drugs  
• Development and testing of methods and models of immune responses to cancer and assessing such responses in cancer patients
• Mechanisms of tumor resistance and escape from immune recognition or killing including modulation of tumor antigen processing and presentation, alteration of susceptibility of tumors to innate and adaptive immunologic responses, tumor-induced immune suppression and tolerance

The study sections with most closely related areas of similar science listed in rank order are:

Transplantation, Tolerance and Tumor Immunology Study Section [TTT] 
Clinical Oncology Study Section [CONC] 
Developmental Therapeutics Study Section [DT] 
Radiation Therapeutics and Biology Study Section [RTB]